Akers Biosciences, Inc. Trading Update and Notice of Q2 Results (0747N)
August 03 2017 - 11:30AM
UK Regulatory
TIDMAKR
RNS Number : 0747N
Akers Biosciences, Inc.
03 August 2017
August 3, 2017
Akers Biosciences, Inc.
Trading Update
&
Notice of Q2 Results
Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ("Akers
Bio" or the "Company"), a developer of rapid health information
technologies, announces that sales in the second quarter ended June
30, 2017 were among the strongest since the Company's admission to
NASDAQ Capital Market in 2014.
The Company recorded revenues of approximately $1.2 million over
the three-month period, representing an increase of approximately
25 per cent over the second quarter of 2016, and a 1.8 times
increase over the first quarter of 2017. Revenues were derived from
product sales in all key geographic regions (U.S., China and Rest
of World) and were comprised of sales across Akers Bio's core
commercialized product lines including components associated with
the Company's PIFA Heparin/PF4 Rapid Assay products for sale
internationally, and MPC breathalyzer based products.
Akers Bio intends to file its Form 10-Q containing the financial
statements for the three months and six months ended June 30, 2017
after U.S. market close on Monday, August 14, 2017. A summary of
the results will be published in the U.K. via the Regulatory News
Service at 07:00 a.m. on Tuesday, August 15, 2017.
Notice of Conference Call
Akers Bio will hold a conference call on Tuesday, August 15,
2017 at 2:00 p.m. BST (09:00 a.m. EST) to discuss its earnings for
the three months and six months ended June 30, 2017. Management
will be available during a question-and-answer session.
To participate in the call from outside the U.S., please dial
1-719-457-2602 approximately 10 minutes prior to the scheduled
start time. Callers from within the U.S. should dial
1-800-210-9006. The Conference ID is 7353698. Interested parties
can also listen via a live Internet webcast, which can be found at
http://public.viavid.com/index.php?id=125855.
A recording of the call will be available in the Investor Center
of the Company's website at
http://www.akersbio.com/investor-center.
About Akers Biosciences, Inc.
Akers Bio develops, manufactures, and supplies rapid screening
and testing products designed to deliver quicker and more
cost-effective healthcare information to healthcare providers and
consumers. The Company has advanced the science of diagnostics
while responding to major shifts in healthcare through the
development of several proprietary platform technologies. The
Company's state-of-the-art rapid diagnostic assays can be performed
virtually anywhere in minutes when time is of the essence. The
Company has aligned with major healthcare companies and high volume
medical product distributors to maximize product offerings, and to
be a major worldwide competitor in diagnostics.
Additional information on the Company and its products can be
found at www.akersbio.com. Follow us on Twitter @AkersBio.
Cautionary Statement Regarding Forward Looking Statements
Statements contained herein that are not based upon current or
historical fact are forward-looking in nature and constitute
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. Such forward-looking statements reflect the Company's
expectations about its future operating results, performance and
opportunities that involve substantial risks and uncertainties.
These statements include but are not limited to statements
regarding the intended terms of the offering, closing of the
offering and use of any proceeds from the offering. When used
herein, the words "anticipate," "believe," "estimate," "upcoming,"
"plan," "target", "intend" and "expect" and similar expressions, as
they relate to Akers Biosciences, Inc., its subsidiaries, or its
management, are intended to identify such forward-looking
statements. These forward-looking statements are based on
information currently available to the Company and are subject to a
number of risks, uncertainties, and other factors that could cause
the Company's actual results, performance, prospects, and
opportunities to differ materially from those expressed in, or
implied by, these forward-looking statements.
For more information:
Akers Biosciences, Inc.
John J. Gormally, Chief Executive Officer
Raymond F. Akers, Jr. PhD, Vice Chairman & Chief Scientific
Director
Tel. +1 856 848 8698
finnCap (UK Nominated Adviser and Broker)
Adrian Hargrave / Scott Mathieson (Corporate Finance)
Steve Norcross (Broking)
Tel. +44 (0)20 7220 0500
Vigo Communications (Global Public Relations)
Ben Simons / Fiona Henson
Tel. +44 (0)20 7830 9704
Email: akers@vigocomms.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
TSTBUGDIBBGBGRX
(END) Dow Jones Newswires
August 03, 2017 11:30 ET (15:30 GMT)
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From Sep 2023 to Sep 2024